Edition:
United Kingdom

Zealand Pharma A/S (ZEAL.OQ)

ZEAL.OQ on NASDAQ Stock Exchange Global Select Market

13.93USD
18 Oct 2018
Change (% chg)

$-0.23 (-1.62%)
Prev Close
$14.16
Open
$14.16
Day's High
$14.16
Day's Low
$13.85
Volume
537
Avg. Vol
3,656
52-wk High
$18.91
52-wk Low
$12.01

Latest Key Developments (Source: Significant Developments)

Zealand Pharma Achieves Primary And Key Secondary Endpoints In Pivotal Phase 3 Trial With Dasiglucagon For Severe Hypoglycemia
Tuesday, 18 Sep 2018 

Sept 18 (Reuters) - Zealand Pharma A/S ::REG-ZEALAND PHARMA ACHIEVES PRIMARY AND KEY SECONDARY ENDPOINTS IN PIVOTAL PHASE 3 TRIAL WITH DASIGLUCAGON FOR SEVERE HYPOGLYCEMIA.99% OF PATIENTS ON DASIGLUCAGON RECOVERED FROM LOW BLOOD GLUCOSE WITHIN 15 MINUTES.SAYS WILL SOON INITIATE PHASE 3 TRIAL IN PEDIATRIC DIABETES PATIENTS, WHICH IS EXPECTED TO COMPLETE IN MID-2019.  Full Article

Zealand Sells Royalty Streams And Milestones For $205 Mln To Royalty Pharma
Thursday, 6 Sep 2018 

Sept 6 (Reuters) - Zealand Pharma A/S ::REG-ZEALAND SELLS ROYALTY STREAMS AND MILESTONES FOR USD 205 MILLION TO ROYALTY PHARMA.ZEALAND WILL REMAIN ELIGIBLE FOR A PAYMENT FROM SANOFI UP TO USD 15 MILLION, EXPECTED IN 2020.ZEALAND - TO SELL FUTURE ROYALTY STREAMS, $85 MILLION OF POTENTIAL COMMERCIAL MILESTONES FOR SOLIQUA 100/33/ SULIQUA, LYXUMIA/ADLYXIN TO ROYALTY PHARMA.  Full Article

Zealand Pharma Q2 Operating Loss Widens To DKK 131.9 Million
Thursday, 16 Aug 2018 

Aug 16 (Reuters) - Zealand Pharma A/S ::REG-ZEALAND PHARMA - INTERIM REPORT FOR THE FIRST HALF OF 2018.H1 REVENUE OF DKK 24.9 MILLION / USD 3.9 MILLION (DKK 86.7 MILLION / USD 13.3 MILLION IN FIRST HALF OF 2017.Q2 OPERATING LOSS DKK 131.9 MILLION VERSUS OPERATING LOSS DKK 95.5 MILLION YEAR AGO.  Full Article

Zealand Q2 Net Sales Of Soliqua 100/33 And Lyxumi/Adlyxin At DKK 171 Million
Tuesday, 31 Jul 2018 

July 31 (Reuters) - ZEALAND PHARMA A/S ::REG-ZEALAND ANNOUNCES AN 85% INCREASE IN SOLIQUA® 100/33/ SULIQUA® ROYALTY REVENUE FROM FIRST TO SECOND QUARTER OF 2018.NET SALES OF SOLIQUA(®) 100/33/ SULIQUA® AND LYXUMIA®/ADLYXIN® OF DKK 171 MILLION/USD 27 MILLION IN Q2 2018.Q2 SOLIQUA® 100/33/ SULIQUA® ROYALTY REVENUE INCREASED BY 85% OVER PREVIOUS QUARTER.  Full Article

Reg-Zealand Pharma Achieves Milestone In First Phase 3 Trial
Friday, 8 Jun 2018 

June 8 (Reuters) - Zealand Pharma A/S ::REG-ZEALAND PHARMA ACHIEVES MILESTONE IN FIRST PHASE 3 TRIAL WITH DASIGLUCAGON FOR THE TREATMENT OF SEVERE HYPOGLYCEMIA IN DIABETES.RESULTS OF FIRST COMPLETED PHASE 3 TRIALS CONFIRM DASIGLUCAGON'S SAFETY AND EFFICACY PROFILE IN PATIENTS WITH TYPE 1 DIABETES.IN ADDITION TO THIS TRIAL, A SECOND AND PIVOTAL PHASE 3 EFFICACY TRIAL WAS INITIATED LATE 2017 AND LAST PATIENT VISIT OCCURRED IN MAY 2018.FINAL RESULTS ARE EXPECTED IN Q3 2018..  Full Article

Zealand Pharma To Present New Clinical Phase 2 Results On Glepaglutide
Thursday, 31 May 2018 

May 31 (Reuters) - ZEALAND PHARMA A/S ::REG-ZEALAND PHARMA TO PRESENT NEW CLINICAL PHASE 2 RESULTS ON GLEPAGLUTIDE FOR THE TREATMENT OF SHORT BOWEL SYNDROME AT THE DDW CONFERENCE IN THE U.S..RESULTS DEMONSTRATES GLEPAGLUTIDE'S EFFECTS ON INTESTINAL TRANSIT TIME, MORPHOLOGY AND ENERGY ABSORPTION.REMAINS ON TRACK TO INITIATE PIVOTAL PHASE 3 TRIAL, WITH WEEKLY AND TWICE-WEEKLY DOSING OF GLEPAGLUTIDE, IN H2 2018.SUPPORTS PRIMARY RESULTS OF TRIAL, WHICH DEMONSTRATED REDUCTIONS IN DIARRHEA/FECAL OUTPUT AND INCREASES IN INTESTINAL WET WEIGHT ABSORPTION.  Full Article

Zealand Pharma: Phase 3 Trial With Dasiglucagon Successfully Met Primary Objective
Monday, 28 May 2018 

May 28 (Reuters) - ZEALAND PHARMA A/S ::REG-ZEALAND PHARMA REPORTS COMPLETION OF THE SECOND AND PIVOTAL PHASE 3 TRIAL WITH DASIGLUCAGON FOR THE TREATMENT OF SEVERE HYPOGLYCEMIA.KEY RESULTS NOW EXPECTED IN Q3 2018.PHASE 3 TRIAL WITH DASIGLUCAGON FOR TREATMENT OF SEVERE HYPOGLYCEMIA TO HAVE SUCCESSFULLY MET PRIMARY OBJECTIVE IN Q1.  Full Article

Zealand Pharma Q1 Net loss at DKK 91.4 mln
Wednesday, 16 May 2018 

May 16 (Reuters) - Zealand Pharma A/S ::REG-ZEALAND PHARMA - INTERIM REPORT FOR THE FIRST QUARTER OF 2018.Q1 REVENUE DKK 10.8 MILLION VERSUS DKK 77.6 MILLION YEAR AGO.Q1 NET LOSS DKK 91.4 MILLION VERSUS LOSS DKK 26.3 MILLION YEAR AGO.THERE WAS NO MILESTONE REVENUE IN Q1 2018.MAINTAINS ITS FINANCIAL GUIDANCE FOR FULL-YEAR 2018.  Full Article

Zealand Pharma Makes Initial USD 1.5 Mln Equity Investment In Beta Bionics
Thursday, 21 Dec 2017 

Dec 21 (Reuters) - ZEALAND PHARMA A/S ::ZEALAND PHARMA MAKES AN INITIAL USD 1.5 MILLION EQUITY INVESTMENT IN SERIES B OFFERING OF BETA BIONICS, INC..POTENTIAL FUTURE INVESTMENTS OF UP TO USD 3.5 MILLION ARE LINKED TO CLINICAL DEVELOPMENT MILESTONES.COLLABORATES WITH BETA BIONICS TO ADVANCE DEVELOPMENT OF ITS DASIGLUCAGON IN ILET(TM).  Full Article

Zealand Pharma Initiates Phase 3 Trial With Dasiglucagon
Thursday, 7 Dec 2017 

Dec 7 (Reuters) - Zealand Pharma A/S ::ZEALAND PHARMA INITIATES THE PIVOTAL PHASE 3 TRIAL WITH DASIGLUCAGON FOR THE TREATMENT OF SEVERE HYPOGLYCEMIA IN DIABETES.SAYS RESULTS FROM PHASE 3 TRIAL EXPECTED IN H2 2018​.  Full Article

BRIEF-Zealand Q1 Net Sales Of Soliqua 100/33 And Lyxumia/Adlyxin At EUR 14.5 Mln

* REG-ZEALAND ANNOUNCES NET SALES OF SOLIQUA® 100/33 AND LYXUMIA®/ADLYXIN® FOR THE FIRST QUARTER OF 2018